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Bovine Herpesvirus 1 (BHV-1) belongs to the genus of Varicellovirus and the family of Herpesviridae 
which contains three main gB, gC and gD genes. In order to cloning of the coding region of gD gene of 
IBR virus , PCR product of the open reading frame of the gene from IBR virus isolated in Iran was 
amplified by PCR. A 1047bp PCR product of the gD gene with EcoRI, HindIII restriction sites were 
subcloned of pTZ57R/T and digested by the mentioned endonucleases. Digested insert cloned in to 
pET-32a and transfered in E.coli cells. For the expression of gD protein, the pET-32a recombinant 
vector was transformed and then induced in BL21 (DE3) strain of E.coli competent cells using IPTG. 
The presence of gD expressed protein was shown in immunoblotting and SDS-PAGE system. With 
respect to the remarkable frequency of infection to IBR in Iran and the necessity of controlling it 
through vaccination with recombinant vaccines of thymidine kinase, manufacturing and applying the 
recombinant gD protein are vital goals in recognition and distinction between infection and responses 
caused by vaccine. 
 





Bovine herpesvirus 1 (BHV-1), a member of the Alphahe-
rpesvirinae subfamily (Meurens et al., 2004), classified in 
the list B of the Office International des Epizooties 
(Winkler et al., 2000), is an important viral pathogen of 
cattle that causes two major disease syndromes: infectious 
bovine rhinotracheitis (IBR) and infectious pustular 
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et al., 2004). Secondary bacterial infections resulting in 
bronchopneumonia and death are common (Winkler et 
al., 2000). Although IBR was thought to have been 
eradicated in several European countries, it still causes 
economic losses to the European and the U.S. beef 
industries (Meurens et al., 2004). In the nations where 
BHV-1 has not been eradicated, control and eradication 
programs are associated with vaccination strategy with 
live attenuated or inactivated vaccines (Taylor et al., 
1998).  
The glycoprotein C, D, E, G and I, in UL49h and 
thymidine kinase proteins are involved in viral virulence 
and are useful targets for diagnosis, prevention or antiviral 
treatment (Smith et al., 1994; Van Engelenburg et al., 
1994; Young and Smith, 1995; Van Oirschot et al., 1996; 
Schwyzer and Ackermann, 1996; Liang et al., 1996; Liang 
et al., 1997; Kaashoek et al., 1998). Most herpesvirus 
glycoproteins are present in the viral envelope and are 
important for virus-host interactions and are also  necessary  
  




for a productive BHV-1 infection of bovine cells (Chase et 
al., 1990). However, gB, gC and gD have been known as 
the major BHV-1 envelope glycoproteins (Winkler et al., 
2000; Meurens et al., 2004). The lack of information on 
isolated BHV-1 in Iran seems obvious. 
The aim of this study is to clone and express BHV-1 gD 
gene in order to obtain glycoprotein B of the isolated virus 
in Iran. The prepared recombinant protein will be applied 
in future studies to design a Dot-ELISA kit for detecting 
and distinguishing infected and vaccinated cows. In 
addition, this recombinant protein can be use as an antigen 
to prepare monoclonal antibody.  
 
 
MATERIALS AND METHODS 
 
Sample, plasmids and bacterial strains  
 
The extracted DNA from IBR virus isolated in Iran was selected to 
be cloned. Plasmid pTZ57R/T (Ins T/A clone PCR Cloning kit, 
Fermentas) and Escherichia coli strain JM107 (Fermentas) were 
used for initial cloning, sequencing and maintenance of DNA 
fragment. For recombinant protein production, a prokaryotic expression 
vector pET-32a (Novagen) was used. The recombinant pET-32a 
(pET-32a-gD) was transformed into E. coli BL21 (DE3) (Fermentas) 
as host strain. The required antibiotics were added to Luria- Bertani 
(LB) media according to the reference recommendation (Sambrook 
and Russell, 2001). 
 
 
Primers design  
 
Primers were designed according to the published sequence for gD 
gene of IBR (accession number: AY690484.1). The forward primer, 
gD F:5-ATTATAGAATTCATGCAGGGGCCGACATTG-3 contain EcoRI 
site while the reverse primer, gD R:5-TGATTGAAGCTTGT 
GCGTGATGGCCTCG-3 contain recognition site for HindIII. The 
restriction enzyme sites (underlined) were added to the primers for 
subsequent cloning procedure. 
 
 
Gene amplification of gD (encoding the glycoprotein D) 
 
The amplification reaction was performed in 50 µL reaction mixtures 
containing 0.1 mM of each dexoynucteotide, 15 pmoL of each 
primer, 50 mM KCl, 10 mM Tris-HCl (pH = 9), 2 mM MgCl2, 10% 
dimethylsulfoxide (DMSO, Sigma), 1.5 U of Taq DNA polymerase 
(Sigma) and 40 ng of template DNA. The polymerase chain 
reaction (PCR) was carried out in a PCR programmed thermocycler 
(Eppendrof, Mastercycler 5330, Eppendorf-Nethel-Hinz GmbH, 
Hamburg, Germany Co.) using the thermal profiles: initial cycle 
94°C for 9 min, followed by a further 35 cycles; denaturation at 
95°C for 60 s; annealing at 58°C for 60 s and extension by 
polymerase at 72°C for 60 s. The final cycle was run at 72°C for 7 
min (Ros and Belak, 1999). The PCR product was analyzed by 
electrophoresis in 1% agarose gel in 1X TBE buffer and visualized 
by ethidium bromide stain on UV transilluminator. The PCR product 
was purified by high pure PCR product purification kit (Roche 
applied science) according to the manufacturer’s recommendation.  
 
 
Cloning of gD gene  
 
The PCR product was digested with EcoRI and HindIII and ligated 





enzymes, using T4 DNA ligase (Invitrogen) at 14°C over night. E. 
coli JM107 and E. coli BL21 (DE3) competent cells were prepared 
by calcium chloride method and were used for transformation of 
pTZ57R/T-gD and pET-32a-gD vectors, respectively. The transformed 
bacteria were selected by screening the colonies on LB media 
containing antibiotic. The suspected colony was further analyzed by 




Expression and purification of recombinant glycoprotein D  
 
E. coli strain BL21 (DE3) was transformed with pET-32a-gD and 
grown in LB broth supplemented with ampicillin (100 mg/ml) at 
37°C with agitation. In order to optimize the expression condition, 
different concentrations of isopropyl -D-1-thiogalactopyranoside 
(IPTG) (0.5, 0.8, 1 and 1.5 mM) at different bacterial growth rates 
(OD600 = 0.5,0.7,1) were tested for three hours and analyzed on 
17% sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). The expressed protein was purified using Ni-NTA 
column (Qiagene) according to manufacture’s instructions. Quantity 
of the purified recombinant glycoprotein D was analyzed by 
Bradford methods and subsequently, its quality was assayed by 
SDS-PAGE 15% (2.5g/well). In order to analyze the cross-reaction 
between fused segments of tax protein with infected sera, an E. coli 
BL21 (DE3) containing pET-32a vector was induced by IPTG. 
 
 
Immunoblot analysis  
 
For western blot analysis, 0.5 g of purified recombinant glycoprotein 
D was used per well. As a negative control, the bacterial lysate from 
induced E. coli BL21 (DE3) contain pET-32a vector was analyzed 
by western blot. The gel was blotted on to polyvinylidine difluoride 
(PVDF Membrane, Roche Diagnostics GmbH) membrane using 
transfer buffer containing 25 mM Tris (pH = 8.3), 192 mM glycine 
and 20% methanol at 55v for 1 h at 4°C. The blotted membrane 
was blocked with 3% (w/v) bovine serum albumin (BSA) in tris 
buffer saline tween20 (TBST buffer) (0.5 M NaCl, 0.02 M Tris pH = 
8.5, 0.05% Tween 20) for 1 h at room temperature (RT). Membrane 
was incubated for 2 h at 37°C with IBR-infected cow serum, diluted 
1: 25, respectively. Negative serum from apparently health cow that 
had negative results in PCR and enzyme-linked immunosorbent 
assay (ELISA) was used as control. After reaction with the primary 
antibody, the blotted membranes were washed three times with 
TBST and incubated with peroxidase conjugated anti-bovine IgG 
(Sigma) at a 1: 2500 dilution in TBST. The blots were then washed 
three times with TBST and reactions were developed by diamino 





The recombinant plasmid (pET-32a-gD) was sequenced 
by specific primers and Sanger sequencing method 
(Macrogen, Korea). The sequencing result was confirmed 
by comparing with databases and using basic local 
alignment search tool (BLAST) software (data not shown). 
Expression of pET-32a-gD in E. coli BL21 (DE3) was 
induced and the expressed protein was purified by Ni-
NTA column (Figure 1). The result showed that the best 
conditions for recombinant gD protein expression can be 
achieved when 1 mM of IPTG and OD600 = 1 for 3 h was 
used. 
 To determine the reactivity of recombinant  protein gD,  
  






Figure 1. Expression of recombinant gD protein and its purification. Lane 1, protein 
marker; lane 2, pET-32a-gD before induction; lane 3, pET-32a-gD after induction; 




the purified recombinant protein was assayed by western 
blotting method. The infected cattle serum (which had 
previously shown positive serological result based on 
ELISA and AGID) was used. A negative serum from 
disinfected cattle was used as control. Figure 2 illustrates 
the specific interaction between positive serum and 
purified recombinant gD protein. There was no reaction 
between the expressed pET-32a in E. coli BL21 (DE3) 





Herpes virus infections have been reported from all 
continents and most countries in the world. Because of 
the certain nature of these kind of latent infections and 
diseases caused by the causative agent of the infection, 
non-appearance of significant clinical signs during the 
existence of the latent virus in the body as well as 
complicated immunohistochemical, histopathological and 
laboratory diagnosis of these diseases has made herpes 
virus infections to have a worldwide spread in different 
countries. The results of many studies conducted on these 
viruses in humans and animals have provided a wide-
spread field for studying genetic variability, laboratory 
diagnosis, epidemiological studies and finally, appropriate 
strategies for preventing herpes virus infections. Among 
cattles, herpes virus infections, the bovine herpes virus 
type 1 and different diseases caused are significant and 
hence, many widespread researches have been made on 
diagnosis, control and prevention methods for these 
diseases using serologic and molecular biological methods. 
Among BHV-1 structure genes, the ones coding for 
glycoproteins gB, gC and gD are considered as major 
and relatively protected genes and today most molecular 
biological diagnostic methods have been designed based 
on PCR, cloning and on the basis of detection of these 
genes (Yan et al., 2008). gB and gD gene plays main role 
in penetrating BHV-1 virus into a host cell and it acts as 
major viral antibody against protective immune response 
in natural infections due to virus. Those antibodies acting 
against glycoprotein B are considered as a main diagnostic 
arm in most diagnostic serum tests for infections with 
BHV-1(Gao et al., 1994; Kramps et al., 1994; McGeoch 
and Cook, 1994; Ros and Belak, 1999; Ros and Belak, 
2002). 
Anyway, one of the main goals of this examination which 
was tracing of the coding gene of gD protein of IBR in this 
virus, was achieved for the first time in Iran and the 
presence of the corresponding gene was confirmed with 
the help of sequencing of the fragment.  
With respect to the point that primers applied for the 
identification of the gD gene in this study were involved in 
the main part of encoding  frame  of  the  gene,  from  the  
  






Figure 2. Western blot analyses against recombinant gD protein by IBR-
infected serum. Lane 1, protein marker; lane 2, western blotting pET-32a-gD 
before induction; lane 3, western blotting pET-32a-gD after induction; lane 4, 
western blotting purified gD recombinant protein by infected sera; lane 5, 




beginning, the primers were designed for cloning and 
gene expression of gD in a way that the amplified 
fragment could be cloned in different vectors such as 
cloning and expression vectors. 
The second goal of this study was cloning of the 
mentioned gene in each of the cloning vector (pTZ57R/T 
vector) and expressing vector (pET-32a). The cloning of 
this gene in the cloning vector after sequencing and 
comparing resulted sequences to other known sequences 
of the gD gene available in Genbank indicates the 
success in cloning the gene into the related vector. Such 
vectors have the capacity to be proliferated in the 
competent bacterial cells, digested because of several 
sites for restriction enzymes, extracted and inserted into 
the expressing vectors. The last finding was derived by 
cloning the coding gene of gD protein of IBR in the 
expressing vector of pET-32a for the first time in Iran and 
the presence of expressing protein was confirmed 
through SDS-PAGE and immunoblotting system.  
With respect to the remarkable frequency of infection to 
IBR in Iran and the necessity of controlling it through 
vaccination with recombinant vaccines of thymidin 
kinase, manufacturing and applying the recombinant gD 
protein are vital goals in recognition and distinction 
between infection and responses caused by vaccine. As 
the amplified fragment by PCR involves all the domains 
of gD and were placed in the expressing frame based on 
first designs of primers and has been successfully cloned 
in the expression vector of pET-32a, the expression of 
this gene and the prepared recombinant protein will be 
applied in the near future for designing Dot-ELISA kit for 
detection of antibodies against gD antigen of IBR in 
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